Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	To compare the efficacy of treatment with COVID-19 Hyper-Immuneglobulin (Human) plus standard of care versus only standard of care in participants with active COVID-19Timepoint: Mean change from Day 1 to Day 8 in clinical outcome of treatment with COVID-19 Hyper-Immuneglobulin (Human) as compared to the control arm as assessed by 8-point ordinal scale	To compare the efficacy of treatment with COVID-19 Hyper-Immuneglobulin (Human) plus standard of care versus only standard of care in participants with active COVID-19Timepoint: Mean change from Day 1 to Day 8 in clinical outcome of treatment with COVID-19 Hyper-Immuneglobulin (Human) as compared to the control arm as assessed by 8-point ordinal scale
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Nov. 6, 2020, 11:45 p.m.	oms	To compare the efficacy of treatment with COVID-19 Hyper-Immuneglobulin (Human) plus standard of care versus only standard of care in participants with active COVID-19Timepoint: Mean change from Day 1 to Day 8 in clinical outcome of treatment with COVID-19 Hyper-Immuneglobulin (Human) as compared to the control arm as assessed by 8-point ordinal scale	To compare the efficacy of treatment with COVID-19 Hyper-Immuneglobulin (Human) plus standard of care versus only standard of care in participants with active COVID-19Timepoint: Mean change from Day 1 to Day 8 in clinical outcome of treatment with COVID-19 Hyper-Immuneglobulin (Human) as compared to the control arm as assessed by 8-point ordinal scale